Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:4.6.1.1 (
adenylate cyclase
)
19,190
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
An important factor in regulating secretion from endocrine cells is the cytoplasmic concentration of cyclic-AMP. Many regulatory substances are known to either stimulate or inhibit the production of this second messenger through activation of their receptors. In the present study, we have monitored changes in cyclic-AMP efflux from melanotrope cells of Xenopus laevis in response to established neurochemical regulators of alpha-MSH secretion. In vitro superfusion of neurointermediate lobes allows for a dynamic recording of cyclic-AMP production in relation to hormone secretion. Unlike alpha-MSH secretion, the efflux of cyclic-AMP was not dependent on the concentration of extracellular calcium, indicating that hormone release and cyclic-AMP efflux are mediated by different mechanisms. The phosphodiesterase inhibitor IBMX and the
adenylate cyclase
activator forskolin stimulated cyclic-AMP efflux, but had no stimulatory effect on alpha-MSH release. This indicates that an increase in cyclic-AMP production in melanotrope cells is not necessarily accompanied by an increase in the rate of alpha-MSH release.
Corticotropin-releasing factor
stimulated cyclic-AMP efflux with dynamics similar to that induced by the amphibian peptide sauvagine. Dopamine and the GABAB receptor agonist baclofen both inhibited cyclic-AMP efflux and alpha-MSH release, with similar dynamics of inhibition and similar dose-response relationships. It is proposed that an inhibition of cyclic-AMP efflux is coupled to an inhibition of alpha-MSH secretion.
...
PMID:Dynamics of cyclic-AMP efflux in relation to alpha-MSH secretion from melanotrope cells of Xenopus laevis. 127 39
The two fundamental parameters of corticotropin (ACTH) secretion are the number of secreting corticotropes and the amount of ACTH secreted by each cell. We have measured these parameters in rat corticotropes in response to increasing concentrations of
corticotropin-releasing factor
(
CRF
) or arginine vasopressin (AVP). Increasing concentrations of AVP stimulated more corticotropes to secrete, while the amount of ACTH each cell secreted remained relatively fixed (nongraded secretory response). Conversely, increasing concentrations of
CRF
stimulated more ACTH secretion per cell (graded secretory response), while the number of secretory cells remained relatively constant. When viewed from the perspective of a single corticotrope, it was clear that
CRF
and AVP induced completely distinct specific responses. We have previously shown, and provide further evidence here, that secretory responses to
CRF
or AVP occur in the same cell. It is therefore apparent that a single corticotrope is able to generate either a graded, or a nongraded secretory response. We have also considered the potential intracellular changes that must direct graded or nongraded secretion. It is generally accepted that
CRF
stimulates activation of
adenylate cyclase
, whereas AVP activates phosphoinositidase in pituitary corticotropes. Our findings, and others surveyed here, suggest that the activation of
adenylate cyclase
results in graded secretion, while the activation of phosphoinositidase induces the nongraded secretion. Graded or nongraded secretion may therefore be linked to specific second messengers. It is hypothesized that the inositol 1,4,5-trisphosphate-mediated release of an intracellular Ca2+ store constitutes a mechanism whereby phosphoinositidase-coupled hormones set in motion the nongraded secretory response. These findings suggest novel functions for individual second messengers.
...
PMID:Corticotropin-releasing factor, but not arginine vasopressin, stimulates concentration-dependent increases in ACTH secretion from a single corticotrope. Implications for intracellular signals in stimulus-secretion coupling. 131 23
Advances in neuropeptide neurobiology in the last decade are illustrated by studies of
corticotropin-releasing factor
(
CRF
), the 41 amino acid-containing peptide that controls the anterior pituitary secretion of adrenocorticotropin and other pro-opiomelanocortin products.
Corticotropin-releasing factor
is synthesized in both hypothalamic and extrahypothalamic perikarya in a large prohormone form, (186 amino acids), then it is processed and transported to nerve terminals where it is released in its active form by a calcium-dependent mechanism.
Corticotropin-releasing factor
biosynthesis can now be measured by in situ hybridization because of the elucidation of the
CRF
gene sequence. Once released,
CRF
acts on high-affinity
CRF
receptors, and signal transduction is mediated by activation of
adenylate cyclase
in certain brain areas, and perhaps by phosphoinositide hydrolysis. In other brain areas
CRF
is inactivated by peptidases that degrade the hormone, though these are not well characterized. A
CRF
binding protein has been identified in plasma, and perhaps in brain. Considerable evidence exists from cerebrospinal fluid studies, postmortem tissue receptor measurements, and
CRF
stimulation test studies to support the hypothesis that
CRF
is hypersecreted in depression, resulting in both pituitary-adrenal axis hyperactivity and certain signs and symptoms of depression, e.g., decreased libido, insomnia, and decreased appetite. There is also evidence for an involvement of
CRF
in the pathophysiology of anxiety disorders and in the mechanism of action of benzodiazepines. The development of selective
CRF
-receptor antagonists will permit direct testing of the hypothesis that
CRF
hypersecretion is responsible for certain of the cardinal features of affective and anxiety disorders.
...
PMID:New vistas in neuropeptide research in neuropsychiatry: focus on corticotropin-releasing factor. 161 Apr 87
1.
Corticotropin-releasing factor
(
CRF
) plays a major role in the endocrine, autonomic and behavioral responses to stress. The distribution of
CRF
and
CRF
receptors in hypothalamic and extra-hypothalamic brain regions is consistent with its stress-related functions. 2. In most brain regions,
CRF
acts primarily, if not exclusively, through activation of the
adenylate cyclase
systems. 3. While previous studies have demonstrated the prenatal presence of
CRF
receptors, in the early postnatal period the abundance of
CRF
receptors relative to the magnitude of
CRF
-stimulated cAMP production suggests that
CRF
receptors are not fully linked to
adenylate cyclase
. 4. Because of our interest in the possible involvement of
CRF
signal transduction in the development of the neonatal stress response, we have examined postnatal development of
CRF
receptors in relation to
adenylate cyclase
activity in the rat. 5.
CRF
binding decreased significantly in the hippocampus and striatum from postnatal days 7-21. Basal
adenylate cyclase
activity peaked in the second-third week of postnatal life in each brain region. Preliminary studies suggest that early stress can alter the maturation of second messenger systems in the frontal cortex.
...
PMID:Postnatal development of regional binding of corticotropin-releasing factor and adenylate cyclase activity in the rat brain. 164 99
Interleukin 6 (IL-6) production was shown to be stimulated by vasoactive intestinal peptide via cAMP dependent signal transduction pathway in the pituitary. We were interested in whether other hypothalamic neuropeptides, which activate
adenylate cyclase
in the pituitary, also stimulate pituitary IL-6 production. Whereas vasoactive intestinal peptide was effective in stimulating pituitary IL-6 production only at concentrations of 10(-6) M or higher, pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38) and calcitonin gene-related peptide (CGRP) at concentrations from 10(-10) to 10(-9) M significantly stimulated IL-6 production. Similar effective concentrations of each peptide were required for activating
adenylate cyclase
, as measured by extracellular cAMP accumulation. H89, a specific inhibitor of cAMP dependent protein kinase (protein kinase A), inhibited IL-6 production stimulated by PACAP38, CGRP, and (Bu)2cAMP. However, H89 failed to inhibit the IL-6 production stimulated by lipopolysaccharide, a ligand which enhanced IL-6 production in the absence of cAMP accumulation. Two other peptides which are known to activate pituitary
adenylate cyclase
,
corticotropin-releasing factor
and GRF failed to stimulate IL-6 production in pituitary cells. Using discontinuous Percoll gradients to fractionate the pituitary cells, the greatest PACAP38-stimulated IL-6 secretion was observed in the low density fraction 1 (F1). This fraction also contained the highest percentage of folliculo-stellate (FS) cells, one of the nonhormone secreting pituitary cells. However, the largest PACAP38-induced accumulation of cAMP was observed in F4. These results suggest that the production of IL-6 stimulated by PACAP and CGRP is mediated by the
adenylate cyclase
/protein kinase A signal transduction system. FS cells appear to be the most likely target cell type for PACAP-induced IL-6 production. However, IL-6 producing FS cells may not be an exclusive target for PACAP in the pituitary.
...
PMID:Neuropeptide regulation of interleukin-6 production from the pituitary: stimulation by pituitary adenylate cyclase activating polypeptide and calcitonin gene-related peptide. 165 84
We have recently demonstrated the presence in the rat Leydig cells of a
corticotropin releasing factor
(
CRF
) receptor and an inhibitory action of the peptide on human chorionic gonadotropin (hCG)-induced cAMP generation and steroidogenesis. The inhibitory action of
CRF
was unaffected by pertussis toxin and was completely reversed by 8-bromo-cAMP (Ulisse, S., Fabbri, A., and Dufau, M. L. (1989) J. Biol. Chem. 264, 2156-2163). In this study, we have evaluated the participation of protein kinase C in
CRF
action in the Leydig cells and the level of the gonadotropin signal pathway affected by
CRF
. Binding of 125I-labeled ovine
CRF
to Leydig cell membranes was reduced by GTP and guanyl-5'-yl imidodiphosphate (Gpp(NH)p), in a dose-dependent manner. Phorbol 12-myristate 13-acetate, like
CRF
, caused time-dependent inhibition of hCG-induced cAMP generation and steroidogenesis. This inhibitory action was reversed by 8-bromo-cAMP. Both
CRF
and 12-O-tetradecanoylphorbol-13-acetate did not affect 125I-hCG binding. No additive effects of
CRF
and the phorbol ester were observed in these studies.
CRF
caused a rapid translocation of protein kinase C in Leydig cells. Preincubation of cells with protein kinase C inhibitors or TPA-induced depletion of protein kinase C prevented the inhibitory actions of
CRF
and TPA.
CRF
and TPA were able to inhibit the stimulation of cAMP and testosterone production by cholera toxin and forskolin. Adenylate cyclase stimulation by Gpp(NH)p, luteinizing hormone + Gpp(NH)p, and NaF in crude membranes or by forskolin and manganese in solubilized membranes, prepared from
CRF
- and TPA-treated cells, was also markedly inhibited. We conclude that
CRF
receptors interact with a pertussis toxin-insensitive G protein (possibly Gp) in the Leydig cell and that the inhibitory action of
CRF
on Leydig cell function is exerted mainly on the catalytic subunit of
adenylate cyclase
through a direct or indirect action of protein kinase C.
...
PMID:A novel mechanism of action of corticotropin releasing factor in rat Leydig cells. 215 73
Corticotropin-releasing factor
(
CRF
) stimulates rat retinal
adenylate cyclase
activity in a concentration-dependent manner. The half-maximal effect is obtained at 50 nM
CRF
and the maximal stimulation corresponds to approximately 90% increase of basal enzyme activity. The
CRF
effect is counteracted by the
CRF
antagonist alpha-helical
CRF
9-41 with a Ki value of 40 nM. Other
CRF
-like peptides such as sauvagine and urotensin I are as effective as
CRF
with a rank order of potency of urotensin I greater than or equal to sauvagine greater than
CRF
. The sauvagine and urotensin I effects are not additive with that elicited by
CRF
. Moreover, the
CRF
stimulation is not additive with the increase of enzyme activity produced by vasoactive intestinal peptide or dopamine. The
CRF
effect is independent of the concentration of free Ca2+, is optimal at 5-10 mM MgCl2, and requires GTP. The results indicate that rat retinal
adenylate cyclase
is modulated by
CRF
via a receptor-mediated mechanism.
...
PMID:Presence of corticotropin-releasing factor-stimulated adenylate cyclase activity in rat retina. 215 80
An adenosine-sensitive
adenylate cyclase
has been demonstrated in anterior pituitary cultured cells in the present studies. N-ethylcarboxamideadenosine (NECA), L-N6-phenylisopropyladenosine (PIA), and 5'-N-methylcarboxamideadenosine (MECA), all stimulated
adenylate cyclase
in a concentration-dependent manner in the order of potency NECA greater than PIA greater than MECA. Adenosine showed a biphasic effect on
adenylate cyclase
: stimulation at lower and inhibition at higher concentrations, whereas 2'-deoxyadenosine only inhibited
adenylate cyclase
in a concentration-dependent manner. The stimulatory effect of NECA on
adenylate cyclase
was dependent on metal ion concentrations and was blocked by 3-isobutyl-1-methylxanthine and 8-phenyltheophylline. Various agonists such as isoproterenol, prostaglandins (PGE1), vasoactive intestinal peptide,
corticotropin-releasing factor
, NaF, and forskolin, all stimulated
adenylate cyclase
to various degrees. The stimulatory effect of vasoactive intestinal peptide and
corticotropin-releasing factor
on
adenylate cyclase
was found to be almost additive with the stimulation exerted by NECA. These data indicate the presence of adenosine stimulatory receptors ('Ra') in anterior pituitary which are coupled to
adenylate cyclase
. It is possible that adenosine may act as one of the important regulators to regulate and/or modulate the effects of agents/factors in the release of pituitary hormones.
...
PMID:Adenosine-sensitive adenylate cyclase in rat anterior pituitary. 241 83
The potentiation of
corticotropin-releasing factor
(
CRF
)-stimulated cAMP production by vasopressin (VP) in the pituitary cell was investigated by studies on the interaction of
CRF
, VP, and the protein kinase C activator, phorbol 12-myristate 13-acetate (PMA) on cAMP,
adenylate cyclase
and phosphodiesterase. Addition of VP or PMA (0.01-100 nM) alone did not alter cellular cAMP content, but markedly increased the effect of 10 nM
CRF
with ED50 of about 1 nM. Treatment of the cells with 200 ng/ml pertussis toxin for 4 h increased
CRF
-stimulated cAMP accumulation by 3.2-fold, an effect that was not additive to those of VP and PMA. Incubation of pituitary cells with 2 mM 1-methyl-3-isobutylxanthine increased
CRF
-stimulated cAMP accumulation and decreased the relative effect of VP and PMA, suggesting that the actions of VP and PMA are partially due to inhibition of phosphodiesterase. This was confirmed by the demonstration of a 30% inhibition of the low-affinity phosphodiesterase activity in cytosol and membranes prepared from cells preincubated with VP or PMA. In intact cells, following [3H]adenine prelabeling of endogenous ATP pools, measurement of
adenylate cyclase
in the presence of 1-methyl-3-isobutylxanthine showed no effect of VP and PMA alone, but did show a 2-fold potentiation of the effect of
CRF
. Measurement of
adenylate cyclase
in pituitary homogenates by conversion of [alpha-32P]ATP to [32P]cAMP showed a paradoxical GTP-dependent inhibition by VP of basal and
CRF
-stimulated
adenylate cyclase
activity, suggesting that the VP receptor is coupled to an inhibitory guanyl nucleotide-binding protein. Pertussis toxin pretreatment of the cells prevented the VP inhibition of
adenylate cyclase
activity observed in pituitary cell homogenates. These findings indicate that besides inhibition of phosphodiesterase, VP has a dual interaction with the pituitary
adenylate cyclase
system; a direct inhibitory effect, manifested only in broken cells, that is mediated by a receptor-coupled guanyl nucleotide-binding protein, and a physiologically predominant indirect stimulatory effect in the intact cell, mediated by protein kinase C phosphorylation of one of the components of the
CRF
-activated
adenylate cyclase
system.
...
PMID:Phorbol 12-myristate 13-acetate and vasopressin potentiate the effect of corticotropin-releasing factor on cyclic AMP production in rat anterior pituitary cells. Mechanisms of action. 243 73
Rat Leydig cells possess functional high affinity receptors for
corticotropin-releasing factor
(
CRF
).
CRF
inhibited human chorionic gonadotropin (hCG)-induced androgen production in cultured fetal and adult Leydig cells in a dose-dependent manner, but it had no effect on basal testosterone secretion. Comparable inhibitory effects of
CRF
were observed in the presence or absence of 3-isobutyl-1-methylxanthine.
CRF
treatment caused a marked reduction of steroid precursors of the androgen pathway (from pregnenolone to testosterone) during gonadotropin stimulation, but it did not influence their basal levels. The inhibitory action of
CRF
on hCG-induced steroidogenesis was fully reversed by 8-bromo-cAMP but was not affected by pertussis toxin. The action of
CRF
was rapid; and it was blocked by coincubation with anti-
CRF
antibody.
CRF
caused no changes in hCG binding to Leydig cells, and in contrast to other target tissues,
CRF
did not stimulate cAMP production, indicating that
CRF
receptors are not coupled to Gs in Leydig cells. These studies have demonstrated that
CRF
-induced inhibition of the acute steroidogenic action of hCG is exerted at sites related to receptor/cyclase coupling or cAMP formation. The inhibitory effects of
CRF
in the Leydig cell do not occur through the Gi unit of
adenylate cyclase
, but could involve pertussis toxin-insensitive G protein(s). These observations demonstrate that
CRF
has a novel and potent antireproductive effect at the testicular level. Since
CRF
is synthesized in the testis and is present in Leydig cells, it is likely that locally produced
CRF
could exert negative autocrine modulation on the stimulatory action of luteinizing hormone on Leydig cell function.
...
PMID:Corticotropin-releasing factor receptors and actions in rat Leydig cells. 246 87
1
2
3
4
5
6
7
8
9
10
Next >>